Estimation of Spexin level and some biochemical indicators in obese and non-obese woman's with polycystic ovary syndrome

Main Article Content

Zainab Eskander Mahmood
Sayran Sattar Saleh

Keywords

Periodontitis, Estimation, Control

Abstract

The research aimed to measure the level of the hormone spexin and a number of biochemical variables, including (glucose, cholesterol (ch), triglycerides (T.G), very low-density lipoproteins (VLDL), low-density lipoproteins (LDL), high-density lipoproteins ( HDL) in obese, non-obese, non (PCOS) women.
The research was conducted on (90) blood samples, 60 samples from patients with (PCOS) and 30 of them were healthy females. Blood samples were collected from women attending outpatient clinics in Kirkuk Governorate, after their diagnosis. By obstetrics and gynecology doctors for the period from 11/20/2021 to 25/2/2022, as their ages ranged between (17-42) years, and they according to the body mass index, into three groups was divided, The first group (30) samples for patients with (PCOS) who are obese with BMI of more than 30 kg / m2, and the second group (30) samples for ladies without obesity who have polycystic ovarian syndrome with BMI less than 25 kg / m2, and the third group (30) samples for non-infected women Those with BMI more than 30 kg/m2 as the control group.
The findings of this research show following:
*A notable reduction (P≤0.05) in the level of the hormone spexin when comparing the obese group of PCOS women with the healthy female, However a significant decrease shown P- value (P≤0.01) when comparing the obese women with PCOS with the non-obese.
* There are non-significant differences in the value of body mass index when comparing between female suffers (PCOS) and healthy individuals, while the results reported rose in ( BMI) when comparing two groups, the probability level (P0.01) women with PCOS who are obese and non-obese.
* P- Value rise (P 0.01) in glucose concentration when comparing obese PCOS patients with control, while the reported showed raised (P≤0.05) when comparing obese PCOS patients with non-obese PCOS patients.
P- Value rise (P≤0.01)) in the booth's concentration triglycerides and very low-density proteins when comparing obese PCOS patients with control, and also when comparing between PCOS individuals with and without obesity.
* Increase that is statistically significant (P 0.05) in the concentration both cholesterol and low-density lipoproteins when comparing obese women with PCOS with control, and no significant differences when comparing between PCOS-afflicted obese and non-obese women.
* A non-significant decrease when concentrating of LDL in obese PCOS patients to compared with healthy individuals. It reported lowered when comparing obese PCOS female with non-obese ones.Estimation of Spexin level and some biochemical indicators in obese and non-obese woman's with polycystic ovarysyndrome

Abstract 173 | pdf Downloads 116

References

1. Liu, H., Xie, J., Fan, L., Xia, Y., Peng, X., Zhou, J. and Ni, X. (2022). Cryptotanshinone protects against PCOS-induced damage of ovarian tissue via regulating oxidative stress, mitochondrial membrane potential, inflammation, and apoptosis via regulating ferroptosis. Oxidative Medicine and Cellular Longevity.
2. Witchel, S.F.; Oberfield, S.E.and Peña, A.S.(2019). Polycystic ovary syndrome: pathophysiology, presentation, and treatment with emphasis on adolescent girls. Journal of the Endocrine Society; 3(8); 1545-1573.
3. Shaaban, Z., Khoradmehr, A., Amiri-Yekta, A., Nowzari, F., Jafarzadeh Shirazi, M. R. and Tamadon, A. (2021). Pathophysiologic Mechanisms of Insulin Secretion and Signaling-Related Genes in Etiology of Polycystic Ovary Syndrome. Genetics Research, 2021. 19-
4. Halder, A. and Kumar, H. (2020). Polycystic Ovary Syndrome (PCOS): The Pros and Cons of Various Diagnostic Criteria. EC Gynaecology, 9, 39-
5. Liao, B., Qiao, J. and Pang, Y. (2021). Central regulation of PCOS: Abnormal neuronal-reproductive-metabolic circuits in PCOS pathophysiology. Frontiers in Endocrinology, 12, 667422. 41.
6. Bacopoulou F, Apostolaki D, Mantzou A,et al(2019).Serum Spexin is Correlated with Lipoprotein (a) and Androgens in Female Adolescents Journal of Clinical Medicine;8(12):2103.
7. Walewski JL, Ge F, Lobdell IV H, et al.( 2014) . Spexin is a novel human peptide that reduces adipocyte uptake of long chain fatty acids and causes weight loss in rodents with diet‐induced obesity. Obesity;22(7):1643-52.
8. Champe, P. C., Harvey, R. A. and Ferrier, D. R.(2008). "Metabolism of Biochemistry" 4th ed USA:Lippic Williams and wikins, Pp. 173.
9. Kaplan, L.A.Amadeo, J.Pesce and steren, C.K.(2003).ʺ Methods in clinical chemistry ʺ .4th ed. Mosby . U.S.A:P:113.
10. Young D.S., (1995)Effect of Drugs on Clinical laboratory Tests, 4th Ed..p3-573 to 3-589.
11. Tietz,N. (1999). Textbook of clinical chemistry . 3reded.C.A.Burtis, E.R. Ashwood , W.B.Saunders.Pp:819-861,1250..
12. Finley PR, Tietz , NW. (1996) . editors. Clinical guide to laboratory tests .WB Saunders company.
13. Andreoli TE, Carpenter J , Griggs RC.(2001) . Cecil essentials of medicine:disorder of lipid metabolism. Herbert PN Philadelphia WB Saunders company. London, Tornto;16:526-32 .
14. Al-Mahdawi, M. A.; Khadhem, H. K. and Al-Jebori, S. R .(2018). Effect of physical activity on sex hormones in polycystic ovary syndrome Iraqi women. Iraqi J of Biotechnology; 17(1): 98-107.
15. Esmaeilzadeh, S.; Andarieh, M.G.; Ghadimi ,R. and Delavar, M.A. .( 2015) Body mass index and gonadotropin hormones (LH & FSH) associate with clinical symptoms among women with
polycystic ovary syndrome. Global J of health science; 7(2): 101.
16. Daghestani, M.H.; Daghestani, M.; Daghistani, M.et al( 2018). A study of ghrelin and leptin levels and their relationship to metabolic profiles in obese and lean Saudi women with polycystic ovary syndrome (PCOS). Lipid in Health and Disease; 17(1): 1-9.
17. Sprung, V. S.; Jones, H.; Pugh, C. J.et al.(2014). Endothelial dysfunction in hyperandrogenic polycystic ovary syndrome is not explained by either obesity or ectopic fat deposition. Clinical Science; 126(1): 67-74.
18. Liu Y, Sun L, Zheng L, et al(2020) . Spexin protects cardiomyocytes from hypoxia-induced metabolic and mitochondrial dysfunction. NaunynSchmiedeberg's Archives of Pharmacology. 1;393(1):25-33.
19. Reyes-Alcaraz A, Lee YN, Son GH, et al (2016). Development of spexinbased human galanin receptor type II-specific agonists with increased stability in serum and anxiolytic effect in mice. Scientific reports. 24;6(1):1-0.
20. Asli, G. and Ismail, D. et al.(2021). Decreased levels of spexin are associated with hormonal and metabolic disturbance in subjects with polycystic ovary syndrome;41(3):408-413.
21. ZHU, J.P.; TENG, Y.C.; Zhou. J.; Lu, W.; TAO, M.F. and JIA, W.P .(2013). Increased mean glucose levels in patients with polycystic ovary syndrome and hyperandrogenemia as determined by continuous glucose monitoring. Acta obstetricia et gynecologica Scandinavica92(2):165-171.
22. Rosenfield, R. L. and Ehrmann, D. A. .(2016). The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocrine reviews: 37(5): 467-520.
23. Guo, F., Gong, Z., Fernando, T., Zhang, L., Zhu, X. and Shi, Y. (2022). The Lipid Profiles in Different Characteristics of Women with PCOS and the Interaction Between Dyslipidemia and Metabolic Disorder
States: Chinese in Study Retrospective A in Population .Frontiers Endocrinology,13.
24. Liu, Q., Xie, Y. J., Qu, L. H., Zhang, M. X. and Mo, Z. C. (2019). Dyslipidemia involvement in the development of polycystic ovary syndrome. Taiwanese Journal of Obstetrics and Gynecology, 58(4), 447-453.
25. Rashidi, H., Tafazoli, M., Jalali, M. T. and Mofrad, A. M. E. (2018). Serum lipid profile and insulin resistance in women with polycystic ovarysyndrome (PCOS). Journal Diabetes Metabolic Disorder Control, 5(3):148-52.
26. Kim, J. J. and Choi, Y. M. (2013). Dyslipidemia in women with polycystic ovary syndrome. Obstetrics and gynecology science, 56(3), 137-142.
27. Osibogun, O., Ogunmoroti, O., & Michos, E. D. (2020). Polycystic ovary syndrome and cardiometabolic risk: opportunities for cardiovascular disease prevention. Trends in cardiovascular medicine, 30(7), 399-404.